Teva Pharmaceutical Industries Ltd. announced the exclusive launch of a generic version of Reyataz1 (atazanavir) capsules in the U.S.
Atazanavir sulfate capsules are a protease inhibitor indicated for use in combination with other antiretroviral agents for the treatment of HIV-1 infection for patients 6 years and older weighing at least 15 kg (33 pounds).
Reyataz had annual sales of approximately $402 million in the U.S., according to IMS data as of October 2017.
“The exclusive launch of our generic version of Reyataz marks our fifth generic product offering for the treatment of HIV-1 infection,” said Brendan O’Grady, executive vice president, North America Commercial at Teva. “Antiviral medications continue to be a focus for Teva Generics, and this is an important addition to our portfolio.”
With nearly 600 generic medicines available, Teva has a large portfolio of FDA-approved generic products on the market, along with more than 100 pending first-to-file opportunities in the U.S. Currently, one in seven generic prescriptions dispensed in the U.S. is filled with a Teva generic product.
1 Reyataz® is a registered trademark of Bristol-Myers Squibb Company
(Source: Teva Pharmaceutical Industries Ltd.)
